A Phase 2 interventional study of Cobimetinib and Paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 53 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-13.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.
Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 87th largest by enrollment of the 361 interventional ones that give a count, is one of 8 that started in 2015, is one of 205 in phase 2, and was the 266th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 249 · Phase 3 69 · Phase 4 10
First in 1994; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 361 interventional studies. Of the 254 that completed or were terminated, 125 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 373 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 78th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2015, is one of 65 in phase 2, and was the 138th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
16 of the studies testing paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT03125928Fox Chase Cancer CenterClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT07580833Health Hope PharmaA Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 373 studies testing paclitaxel in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for metastatic breast cancer (MBC). Participants may continue on study treatment until the development of progressive disease (PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The Cohort I target sample size is 12 participants for the safety run-in stage and approximately 90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety run-in stage of approximately 15 participants followed by an expansion stage of approximately 15 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Disease-Specific Exclusion Criteria
Cobimetinib-Specific Exclusion Criteria
Atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only)
Cardiac Exclusion Criteria
General Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib · Drug: Paclitaxel
Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Paclitaxel · Drug: Placebo
Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib · Drug: Paclitaxel · Drug: Atezolizumab
Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib · Drug: Atezolizumab · Drug: Nab-Paclitaxel
Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Also known as: GDC-0973; RO5514041; XL518
Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
Also known as: MPDL3280A
Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.
Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)
Cohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1
OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 5.25 years)
Cohort I, II, III: Overall Survival (OS)
OS was defined as the time from randomization to death from any cause
Time frame: Randomization up to death from any cause (up to approximately 6.5 years)
Cohort I: Percentage of Participants With Confirmed OR (PR or CR), as Determined by the Investigator Using RECIST v1.1
OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)
Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1
DOR was defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator using RECIST v1.1 or death from any cause during the study, whichever occurred first.
Time frame: Time from the first occurrence of documented objective response to time of relapse or death, whichever occurs first (up to approximately 6.5 years)
Cohort I, II, III: Percentage of Participants With Unconfirmed Overall Response (OR_uc) (Unconfirmed PR or CR), as Determined by the Investigator Using RECIST v1.1
ORR_uc (ORR confirmation not required) was defined as the rate of a PR or CR occurring after randomization as determined by the investigator using RECIST v1.1, confirmation not required. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
Time frame: Randomization up to disease progression or relapse, whichever occurs fist (up to approximately 6.5 years)
Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1
PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 6.5 years)
Cohort I, II, III: Percentage of Participants With Adverse Events (AEs)
Time frame: Randomization up to end of study (up to approximately 6.5 years)
Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib
Time frame: Safety Run-In: Predose (Hour [Hr] 0) on Cycle (Cy) 1 Day (D) 8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)
Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib
Time frame: Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)
Cohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib
Time frame: Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15 (Cy=28 days)
Cohort I, II: Cmax of Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Cohort I, II: Cmin of Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Cohort I: AUC0-tau of Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Cohort III: Cmax of Nab-Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)
Cohort III: Cmin of Nab-Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)
Cohort III: AUC0-tau of Nab-Paclitaxel
Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)
Cohort II, III: Cmax (in Serum) of Atezolizumab
Time frame: Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to end of treatment (EOT); 120 days after EOT (approximately 5.25 years) (Cy=28 days)
Cohort II, III: Cmin (in Serum) of Atezolizumab
Time frame: Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT; 120 days after EOT (approximately 5.5 years) (Cy=28 days)
Cohort II, III: AUC0-tau (in Serum) of Atezolizumab
Time frame: Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT (approximately 5.5 years); 120 days after EOT (approximately 5.5 years) (Cy=28 days)
The study recruited participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who had not received prior systemic therapy for metastatic breast cancer. Locally advanced disease must not have been amenable to resection with curative intent.
| Milestone | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|---|
| Started | 16 | 43 | 47 | 32 | 31 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 16 | 43 | 47 | 32 | 31 |
| Withdrew: Death | 7 | 29 | 32 | 23 | 14 |
| Withdrew: Lost to follow-up | 1 | 3 | 3 | 1 | 0 |
| Withdrew: Various reasons | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 7 | 9 | 5 | 13 |
| Withdrew: Withdrawal by subject | 5 | 4 | 2 | 1 | 3 |
PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.
| Weeks | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel |
|---|---|---|
| Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 23.71 (18.14 to 32.14) | 16.43 (8.14 to 31.14) |
OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
| Percentage of participants | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|
| Responders | 37.5 | 32.3 |
| Non-Responders | 62.5 | 67.7 |
OS was defined as the time from randomization to death from any cause
| Months | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|
| Cohort I, II, III: Overall Survival (OS) | 16.72 (13.50 to 20.24) | 19.58 (14.75 to 29.37) | 11.04 (9.53 to 22.51) | 15.57 (14.26 to NA) |
OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
| Percentage of participants | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel |
|---|---|---|
| Responders | 38.3 | 20.9 |
| Non-responders | 61.7 | 79.1 |
DOR was defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator using RECIST v1.1 or death from any cause during the study, whichever occurred first.
| Months | Cohort I: Safety Run-In | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|---|
| Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1 | 39.29 (23.14 to 56.29) | 23.14 (16.14 to 26.57) | 24.14 (17.14 to NA) | 5.78 (4.44 to 16.33) | 11.42 (5.78 to 17.94) |
ORR_uc (ORR confirmation not required) was defined as the rate of a PR or CR occurring after randomization as determined by the investigator using RECIST v1.1, confirmation not required. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.
| Percentage of participants | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|
| Responders | 42.6 | 25.6 | 46.9 | 45.2 |
| Non-Responders | 57.4 | 74.4 | 53.1 | 54.8 |
PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
| Months | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|
| Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1 | 3.75 (3.02 to 7.29) | 7.66 (3.65 to 11.04) |
| Participants | Cohort I: Safety Run-In | Cohort I: Cobimetinib, Paclitaxel | Cohort I: Placebo, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|---|
| Cohort I, II, III: Percentage of Participants With Adverse Events (AEs) | 15 | 46 | 43 | 32 | 30 |
| Nanograms per millilitre (ng/mL) | Cohort I: Safety Run-In | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|
| Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib | 285 ± 62.2 | 266 ± 82.0 | 213 ± 68.0 | 407 ± 90.7 |
| ng/mL | Cohort I: Safety Run-In | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|
| Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib | 65.6 ± 1279.5 | 130 ± 190.7 | 138 ± 79.0 | 136 ± 67.2 |
| Nanograms/milliliter/hour (hr*ng/mL) | Cohort I: Safety Run-In |
|---|---|
| Cohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib | 1620 ± 80.0 |
| ng/mL | Cohort I: Safety Run-In | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab |
|---|---|---|
| Cohort I, II: Cmax of Paclitaxel | 1770 ± 553.4 | 283 ± 490.9 |
| ng/mL | Cohort I: Safety Run-In | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab |
|---|---|---|
| Cohort I, II: Cmin of Paclitaxel | 1.40 ± 89.9 | 1.26 ± 53.3 |
| hr*ng/mL | Cohort I: Safety Run-In |
|---|---|
| Cohort I: AUC0-tau of Paclitaxel | 4220 ± 310.4 |
| ng/mL | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|
| Cohort III: Cmax of Nab-Paclitaxel | 277 ± 658.5 |
| ng/mL | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|
| Cohort III: Cmin of Nab-Paclitaxel | 2.05 ± 173.9 |
No measurements were reported for this outcome.
| ng/mL | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|
| Cohort II, III: Cmax (in Serum) of Atezolizumab | 346 ± 48.3 | 374 ± 38.8 |
| ng/mL | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|
| Cohort II, III: Cmin (in Serum) of Atezolizumab | 144 ± 34.6 | 109 ± 89.9 |
No measurements were reported for this outcome.
Collected over From randomization up until 6.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I: Safety Run-In | 7/16 (43.8%) | 6/16 (37.5%) | 15/16 (93.8%) |
| Cohort I: Placebo, Paclitaxel | 29/43 (67.4%) | 8/43 (18.6%) | 43/43 (100%) |
| Cohort I: Cobimetinib, Paclitaxel | 32/47 (68.1%) | 17/47 (36.2%) | 46/47 (97.9%) |
| Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | 23/32 (71.9%) | 16/32 (50%) | 32/32 (100%) |
| Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab | 14/31 (45.2%) | 15/30 (50%) | 29/30 (96.7%) |
| Event | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|---|
| PYREXIAGeneral disorders | 2/16 | 0/43 | 6/47 | 4/32 | 2/30 |
| CELLULITISInfections and infestations | 0/16 | 0/43 | 4/47 | 1/32 | 0/30 |
| DIARRHOEAGastrointestinal disorders | 0/16 | 0/43 | 1/47 | 2/32 | 2/30 |
| MASTITISInfections and infestations | 0/16 | 0/43 | 0/47 | 1/32 | 2/30 |
| URINARY TRACT INFECTIONInfections and infestations | 0/16 | 1/43 | 3/47 | 0/32 | 2/30 |
| MITRAL VALVE INCOMPETENCECardiac disorders | 1/16 | 0/43 | 0/47 | 0/32 | 0/30 |
| ASTHENIAGeneral disorders | 1/16 | 1/43 | 0/47 | 0/32 | 0/30 |
| MUCOSAL INFLAMMATIONGeneral disorders | 0/16 | 0/43 | 0/47 | 2/32 | 0/30 |
| ERYSIPELASInfections and infestations | 1/16 | 0/43 | 1/47 | 0/32 | 0/30 |
| BRAIN OEDEMANervous system disorders | 1/16 | 0/43 | 0/47 | 0/32 | 0/30 |
| Event | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab |
|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 10/16 | 13/43 | 36/47 | 21/32 | 27/30 |
| RASHSkin and subcutaneous tissue disorders | 8/16 | 5/43 | 22/47 | 12/32 | 17/30 |
| NAUSEAGastrointestinal disorders | 7/16 | 18/43 | 20/47 | 13/32 | 15/30 |
| ALOPECIASkin and subcutaneous tissue disorders | 5/16 | 19/43 | 21/47 | 8/32 | 10/30 |
| ANAEMIABlood and lymphatic system disorders | 3/16 | 6/43 | 12/47 | 14/32 | 10/30 |
| VOMITINGGastrointestinal disorders | 5/16 | 7/43 | 8/47 | 9/32 | 12/30 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 6/16 | 0/43 | 10/47 | 5/32 | 7/30 |
| FATIGUEGeneral disorders | 3/16 | 15/43 | 13/47 | 11/32 | 10/30 |
| STOMATITISGastrointestinal disorders | 5/16 | 5/43 | 13/47 | 5/32 | 5/30 |
| NEUTROPENIABlood and lymphatic system disorders | 2/16 | 13/43 | 8/47 | 6/32 | 8/30 |
The intent-to-treat (ITT) population was defined as all enrolled participants, whether or not the assigned study treatment was received.
| Age, Continuous(Years) | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab | Total |
|---|---|---|---|---|---|---|
| Mean | 53.6 ± 12.7 | 52.9 ± 13.7 | 54.2 ± 10.3 | 53.7 ± 13.1 | 52.2 ± 11.8 | 53.4 ± 12.1 |
| Sex: Female, Male(Participants) | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 43 | 47 | 32 | 31 | 169 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 7 | 3 | 2 | 3 | 16 |
| Not Hispanic or Latino | 13 | 35 | 41 | 30 | 28 | 147 |
| Unknown or Not Reported | 2 | 1 | 3 | 0 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Cohort I: Safety Run-In | Cohort I: Placebo, Paclitaxel | Cohort I: Cobimetinib, Paclitaxel | Cohort II:Cobimetinib,Paclitaxel,Atezolizumab | Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 9 | 11 | 2 | 5 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 | 1 | 0 | 5 |
| White | 10 | 34 | 32 | 28 | 25 | 129 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 2 | 1 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Aug 2018, 40 months.
Results were first posted in Nov 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobimetinib · Paclitaxel · Atezolizumab